1- alpha hydroxyvitamin D5

Drug Profile

1- alpha hydroxyvitamin D5

Alternative Names: 1α-Hydroxy-Vitamin-D5; 1αVitD5; CARD-024

Latest Information Update: 19 May 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cardiavent
  • Class Antineoplastics; Chemopreventatives; Small molecules; Vitamin D analogues
  • Mechanism of Action Calcitriol receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Cardiovascular disorders; Kidney disorders

Most Recent Events

  • 19 May 2015 CARD 024 development is ongoing in USA (Cardiavent Communication)
  • 19 May 2015 1 alpha hydroxyvitamin D5 is available for licensing as of 19 May 2015. http://www.cardiavent.com (Cardiavent Communication)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top